Display Settings:


Send to:

Choose Destination
J Cataract Refract Surg. 2012 Nov;38(11):2019-28. doi: 10.1016/j.jcrs.2012.05.046.

Laboratory analysis of phacoemulsifier compliance and capacity.

Author information

  • 1Jules Stein Eye Institute and Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.



To compare the compliance and capacity of 7 fluidics modules used by 6 phacoemulsifiers from 3 manufacturers.


Jules Stein Eye Institute, Los Angeles, California, USA.


Experimental study.


Previous-model and current-model phacoemulsifiers from 3 manufacturers were subjected to laboratory analysis of compliance and capacity. Previous-generation models tested included the Legacy Advantec, Whitestar Sovereign Phacoemulsification System, and Millennium Microsurgical System. Current models tested were the Infiniti Vision System with standard and Intrepid cassettes, Whitestar Signature Phacoemulsification System, and Stellaris Vision Enhancement System. To measure compliance, the aspiration line was connected to an electronic pressure transducer and small volumes of fluid were injected or aspirated. To measure capacity, the space between the distal end of the aspiration line and the pump was filled with methylene blue-dyed fluid.


The Legacy was the most compliant phacoemulsifier. The old and new Whitestar systems, Millennium system, and Stellaris system showed similar midrange compliances. The Infiniti Vision System with the Intrepid fluidic management system was the least compliant. The Infiniti cassettes had the greatest capacity, which is a detriment from a surge-control perspective, and Signature cassettes had the least capacity.


The Infiniti Intrepid system had the lowest compliance of the 6 units tested, which is optimum from a surge-control perspective. All other things being equal, the Infiniti should have the safest occlusion-break surge response.


Mr. Injev is an employee of Alcon Laboratories. Dr. Miller is a consultant to and investigator for Alcon Laboratories. Ms. Nejad has no financial or proprietary interest in any material or method mentioned.

Copyright © 2012 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk